A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

Clinical trial NCT05246514 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05246514
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-mutant Non-Small Cell Lung Cancer

Start date: 2022-07-13
Primary completion: 2024-11-04
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.